Skip to main content
SpringerLink
Log in

Psychotropic Drugs, Aging and Community Care

  • Leading Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Wattis JP. Development of health and social services in the UK in the twentieth century. In: Copeland JRM, Abou-Saleh MT, Blazer DG, editors. Principles and practice of geriatric psychiatry. Chichester: Wiley, 1994: 875–8

    Google Scholar 

  2. Department of Health. The care programme approach for people with mental illness referred to the Specialist Psychiatric Services. Joint Health/Social Services Circular, HC(90)23/LASSL(90)11, 1990

    Google Scholar 

  3. Groves T. Countdown to community care: what the changes mean. BMJ 1992; 305: 1489–90

    Article  PubMed  CAS  Google Scholar 

  4. Coles RG, von Abendorff R, Herzberg JL. The impact of a new community mental health team on an inner city psychogeriatric service. Int J Geriatr Psychiatry 1991; 6: 31–9

    Article  Google Scholar 

  5. Rosenvinge H. The multi-disciplinary team. In: Copeland JRM, Abou-Saleh MT, Blazer DG, editors. Principles and practice of geriatric psychiatry. Chichester: Wiley, 1994: 887–90

    Google Scholar 

  6. Ghose K. Prescribing CNS drugs for elderly patients. Drugs Aging 1994; 4: 275–84

    Article  PubMed  CAS  Google Scholar 

  7. Need we poison the elderly so often? [editorial]. Lancet 1988; 2:21-3

  8. Larson DB, Lyons JS, Hohmann AA, et al. Psychotropics prescribed to the US elderly in the early and mid 1980s: prescribing patterns of primary care practitioners, psychiatrists and other physicians. Int J Geriatr Psychiatry 1991; 6: 63–70

    Article  Google Scholar 

  9. Lockwood A, Berbatis CG. Psychotropic drugs in Australia: consumption patterns. Med J Aust 1990; 153: 604–11

    PubMed  CAS  Google Scholar 

  10. Cartwright A, Smith C. Elderly people, their medicines and their doctors. London: Routledge, 1988

    Google Scholar 

  11. Royal College of Physicians. Medication for the elderly. J R Coll Physicians Lond 1984; 18: 7–17

    Google Scholar 

  12. Mann AH, Graham N, Ashby D. The prescription of psychotropic medication in local authority old people’s homes. Int J Geriatr Psychiatry 1986; 1: 25–30

    Article  Google Scholar 

  13. Murphy E. The use of psychotropic drugs in long term care. Int J Geriatr Psychiatry 1989; 4: 1–2

    Article  Google Scholar 

  14. Edwards JG. Selective serotonin reuptake inhibitors. BMJ 1992; 304: 1644–5

    Article  PubMed  CAS  Google Scholar 

  15. Henry JA. A fatal toxicity index for antidepressant poisoning. Acta Pyschiatr Scand 1989; 80 Suppl. 354: 37–45

    Article  Google Scholar 

  16. Freemantle N, House A, Song F, et al. Prescribing selective serotonin reuptake inhibitors as strategy for prevention of suicide. BMJ 1994; 309: 249–53

    Article  PubMed  CAS  Google Scholar 

  17. Isacsson G, Holmgren P, Wasserman D, et al. Use of antidepressants among people committing suicide in Sweden. BMJ 1994; 308: 506–9

    Article  PubMed  CAS  Google Scholar 

  18. Walker R. Which medication compliance device? Pharm J 1992 Nov 7: 605–7

    Google Scholar 

  19. Myers ED, Branthwaite A. Out-patient compliance with antidepressant medication. Br J Psychiatry 1992; 160: 83–6

    Article  PubMed  CAS  Google Scholar 

  20. Howard R, Levy R. Depot antipsychotic medication and the management of behavioural and psychotic symptoms in dementia. Int J Geriatr Psychiatry 1992; 8: 111–4

    Article  Google Scholar 

  21. Marks J. The re-emergence of anti-psychiatry. Hospital Update 1994; 20: 187–90

    Google Scholar 

  22. Jonsson B, Bebbington PE. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994; 164: 665–73

    Article  PubMed  CAS  Google Scholar 

  23. Blazer DG. Epidemiology of depression: prevalence and incidence. In: Copeland JRM, Abou-Saleh MT, Blazer DG, editors. Principles and practice of geriatric psychiatry. Chichester: Wiley, 1994: 519–22

    Google Scholar 

  24. Ames D, Ashby D, Mann AH, et al. Psychiatric illness in elderly residents of Part III homes in one London borough: progress and review. Age Ageing 1988; 17: 249–56

    Article  PubMed  CAS  Google Scholar 

  25. Gerson SC, Plotkin AD, Jarvik LF. Antidepressant drug studies, 1964 to 1986: empirical evidence for aging patients. J Clin Psychopharmacol 1988; 8: 311–22

    Article  PubMed  CAS  Google Scholar 

  26. Katona CLE. New antidepressants in elderly patients. In: Levy R, Howard R, Burns A, editors. Treatment and care in old age psychiatry. Petersfield: Wrightson Biomedical, 1993:157–67

    Google Scholar 

  27. Watts J, Bentham P, Bestley J. Choice of antidepressants by psychiatrists working with old people. Psychiatr Bull 1994; 18: 148–51

    Article  Google Scholar 

  28. Haria M, Fitton A, McTavish D. Trazodone: a review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging 1994; 4: 331–55

    Article  PubMed  CAS  Google Scholar 

  29. Georgotas A, McCue RE. The additional benefit of extending an antidepressant trial past seven weeks in the depressed elderly. Int J Geriatr Psychiatry 1989; 4: 191–5

    Article  Google Scholar 

  30. Paykel ES, Priest RG. Recognition and management of depression in general practice: consensus statement. BMJ 1992; 305: 1198–202

    Article  PubMed  CAS  Google Scholar 

  31. Flint AJ. The optimum duration of antidepressant treatment in the elderly. Int J Geriatr Psychiatry 1992; 7: 617–20

    Article  Google Scholar 

  32. Old Age Depression Interest Group. How long should the elderly take antidepressants? A double-blind placebocontrolled study of continuation/prophylaxis therapy. Br J Psychiatry 1993; 162: 175–82

    Article  Google Scholar 

  33. Kupfer DJ, Frank E, Perel JM, et al. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992; 49: 769–73

    Article  PubMed  CAS  Google Scholar 

  34. Nelson JC, Price LH, Jatlow PI. Neuroleptic dose and desipramine concentrations during combined treatment of unipolar delusional depression. Am J Psychiatry 1986; 143: 1151–4

    PubMed  CAS  Google Scholar 

  35. Finch EJL, Katona CLE. Lithium augmentation in the treatment of refractory depression in old age. Int J Geriatr Psychiatry 1989; 4: 41–6

    Article  Google Scholar 

  36. van Marwijk HWJ, Bekker FM, Nolen WA, et al. Lithium augmentation in geriatric depression. J Affect Disord 1990; 20: 217–23

    Article  PubMed  Google Scholar 

  37. Seth R, Jennings AL, Bindman J, et al. Combination treatment with noradrenaline and serotonin reuptake inhibitors in resistant depression. Br J Psychiatry 1992; 161: 562–5

    Article  PubMed  CAS  Google Scholar 

  38. Livingston G. The scale of the problem. In: Burns A, Levy R, editors. Dementia. London: Chapman and Hall, 1993: 21–35

    Google Scholar 

  39. Burns A. Treatment of non-cognitive features of dementia. In: Levy R, Howard R, Burns A, editors. Treatment and care in old age psychiatry. Petersfield: Wrightson Biomedical, 1993: 47–57

    Google Scholar 

  40. Schneider LS, Pollock VE, Lyness SA. A meta-analysis of controlled trials on neuroleptic treatment in dementia. J Am Geriatr Soc 1990; 38: 553–63

    PubMed  CAS  Google Scholar 

  41. Schneider LS, Sobin P. Treatments for psychiatric symptoms and behavioural disturbances in dementia. In: Burns A, Levy R, editors. Dementia. London: Chapman and Hall, 1993:519–40

    Google Scholar 

  42. Harenko A, Alanen I, Eloverra S, et al. Zuclopenthixol and thioridazine in the treatment of aggressive, elderly patients: a double-blind, controlled multi-centre study. Int J Geriatr Psychiatry 1992; 369-76

  43. Oberholzer AF, Hendricksen C, Monsch AU, et al. Safety and effectiveness of low-dose clozapine in psychogeriatric patients. Int Psychogeriatr 1992; 2: 187–95

    Article  Google Scholar 

  44. McKeith I, Fairburn A, Perry R, et al. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992; 305: 673–8

    Article  PubMed  CAS  Google Scholar 

  45. Williams SW, Byrne EJ, Stokes P. The treatment of diffuse Lewy body disease: a pilot study. Int J Geriatr Psychiatry 1993; 8:731–40

    Article  Google Scholar 

  46. Gleason R, Schneider LS. Carbamazepine treatment of agitation in Alzheimer’s outpatients refractory to neuroleptics. J Clin Psychiatry 1990; 51: 115–8

    PubMed  CAS  Google Scholar 

  47. Lawlor BA, Radcliffe J, Mochlan SE, et al. A pilot placebocontrolled study of trazodone and buspirone in Alheimer’s disease. Int J Geriatr Psychiatry 1994; 9:55–60

    Article  Google Scholar 

  48. Nyth AL, Gottfries CG. The clinical efficacy of Citalopram in treatment of emotional disturbances in dementia disorders. Br J Psychiatry 1990; 157: 894–901

    Article  PubMed  CAS  Google Scholar 

  49. Anand R, Wesnes KA. Cognition-enhancing effects of moclobemide, a reversible MAO inhibitor, in humans. Adv Neurol 1990; 51: 261–8

    PubMed  CAS  Google Scholar 

  50. Eagger SA, Levy R, Sahakian BJ. Tacrine in Alzheimer’s disease. Lancet 1991; 337: 989–92

    Article  PubMed  CAS  Google Scholar 

  51. Byrne EJ, Arie T. Tetrahydroaminoacridine and Alzheimer’s disease. BMJ 1994; 308: 868–9

    Article  PubMed  CAS  Google Scholar 

  52. Wagstaff AJ, McTavish D. Tacrine: a review of its pharmacologic and pharmacokinetic properties and therapeutic efficacy in Alzheimer’s disease. Drugs Aging 1994; 6: 510–40

    Article  Google Scholar 

  53. Chatellier G, Lacomblez L. Tacrine and lecithin in senile dementia of the Alzheimer type: a multi-centre trial. BMJ 1990; 300: 495–9

    Article  PubMed  CAS  Google Scholar 

  54. Maltby N, Broe GA, Creasey H, et al. Efficacy of tacrine and lecithin in mild to moderate Alzheimer’s disease: doubleblind trial. BMJ 1994; 308: 879–83

    Article  PubMed  CAS  Google Scholar 

  55. Naguib M, Levy R. Paranoid states in the elderly and late paraphrenia. In: Jacoby R, Oppenheimer C, editors. Psychiatry in the elderly. Oxford: Oxford Medical, 1991: 758–78

    Google Scholar 

  56. Pearlson GD, Kreger L, Rabins PV, et al. A chart review study of late-onset and early-onset schizophrenia. Am J Psychiatry 1989; 146: 1568–74

    PubMed  CAS  Google Scholar 

  57. Tran-Johnson TK, Harris MJ, Jeste DV. Pharmacological treatment of schizophrenia and delusional disorder in late life. In: Copeland JRM, Abou-Saleh MT, Blazer DG, editors. Principles and practice of geriatric psychiatry. Chichester: Wiley, 1994: 685–92

    Google Scholar 

  58. Marder SR, Van Putten T, Mintz J, et al. Low- and conventional dose maintenance therapy with fluphenazine decanoate: two-year outcome. Arch Gen Psychiatry 1987; 440: 518–21

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mental Health in the Elderly Directorate, Lewisham, UK

    Michael Philpot & Ananth Puranik

  2. Guy’s Mental Health National Health Service Trust, Hither Green Hospital, London, England

    Michael Philpot & Ananth Puranik

Authors
  1. Michael Philpot
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ananth Puranik
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Philpot, M., Puranik, A. Psychotropic Drugs, Aging and Community Care. Drugs & Aging 5, 235–241 (1994). https://doi.org/10.2165/00002512-199405040-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199405040-00001

Keywords

Search

Navigation